← Back
Data updated: Jul 17, 2026
Medexus Pharma, Inc.
Biotech Pharmaceuticals
Medexus Pharma, Inc. is a biotechnology company with 1 FDA-approved products.
2015
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics
Medexus Pharma, Inc.'s Key Drugs
Medexus Pharma, Inc.'s core commercial portfolio centers on Ixinity — its most strategically important drugs approved in the last 15 years.
Medexus Pharma, Inc.'s Recent FDA Approvals
New NDA/BLA approvals for Medexus Pharma, Inc. over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
Medexus Pharma, Inc.'s Therapeutic Areas
Disease areas where Medexus Pharma, Inc. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
Medexus Pharma, Inc. Pipeline Snapshot
Active clinical trials for Medexus Pharma, Inc. across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Ixinity leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2015-04-28
- Latest
- 2015-04-28
- Applications
- 1